The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Official Title: A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Study ID: NCT04975399
Brief Summary: This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 104, Birmingham, Alabama, United States
Local Institution - 105, Scottsdale, Arizona, United States
Local Institution - 106, Tampa, Florida, United States
Local Institution - 108, New York, New York, United States
Local Institution - 107, New York, New York, United States
Local Institution - 101, Milwaukee, Wisconsin, United States
Local Institution - 201, Calgary, Alberta, Canada
Local Institution - 204, Edmonton, Alberta, Canada
Local Institution - 203, Halifax, Nova Scotia, Canada
Local Institution - 202, Toronto, Ontario, Canada
Local Institution - 205, Montreal, Quebec, Canada
Local Institution - 302, Pamplona, Navarra, Spain
Local Institution - 301, Badalona, , Spain
Local Institution - 303, Salamanca, , Spain
Local Institution - 304, Santander, , Spain
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR